Raissa Lerner

TL;DR: It is shown that the anti-inflammatory lipid lipoxin A4 is an endogenous allosteric enhancer of the CB1 cannabinoid receptor, and displayed a CB1 receptor-dependent protective effect against β-amyloid (1–40)-induced spatial memory impairment in mice.

TL;DR: Pepcans are the first endogenous allosteric modulators identified for CB1 receptors and could play an important physiological role in modulating endocannabinoid signaling.

TL;DR: The findings indicate that enhancement of anandamide signaling with URB597 is a promising pharmacological approach for the alleviation of chronic widespread nociception in stress-exposed mice, and thus, it could represent a potential treatment strategy for chronic pain associated with neuropsychiatric disorders in humans.

TL;DR: It is confirmed that CB1 is present at much higher density on hippocampal GABAergic interneurons than glutamatergic neurons, and this selective signalling mechanism raises the possibility of designing novel cannabinoid ligands that differentially activate only a subset of physiological effects of CB1 stimulation, thereby optimizing therapeutic action.

TL;DR: It is hypothesized that the observed decrease of 2-AG levels is probably caused by changes in DAGLα expression and MAGL activity, which can contribute to the existing knowledge about the processes underlying selective vulnerability of the hippocampus to ageing and age-related neurodegeneration.